Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

Journal of Infectious Diseases

Volumn 204, Issue 12, 2011, Pages 1951-1959

  Srivastava, Shashikant ^a   Pasipanodya, Jotam G ^a   Meek, Claudia ^b   Leff, Richard ^b   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HOLLOW FIBER; INOCULATION; MONTE CARLO METHOD; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACOKINETIC VARIABILITY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SOUTH AFRICA;

ANTITUBERCULAR AGENTS; COMPUTER SIMULATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; ISONIAZID; MEDICATION ADHERENCE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 81055143909     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir658     Document Type: Article

References (40)

1. Garner P, Volmink J. Directly observed treatment for tuberculosis. BMJ 2003; 327:823-4. (Pubitemid 37271691)
2. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 2004; 364:417-22.
3. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997; 111:1168-73. (Pubitemid 27200067)
4. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2007; 4:CD003343.
5. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010; 16:264-71.
6. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194-201. (Pubitemid 46080051)
7. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51:2329-36. (Pubitemid 47047307)
8. Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51:3781-8. (Pubitemid 350057771)
9. GumboT, SiyambalapitiyageDonaCS,MeekC, Leff R. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53:3197-204.
10. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985; 66:219-25. (Pubitemid 16150082)
11. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
12. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: World Health Organization, 2010. Report No.: WHO/HTM/TB/2009.420.
13. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. [computer program]. Los Angeles: Biomedical Simulations Resource, 2009.
14. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54:1484-91.
15. Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet 1990; 6:182-6.
16. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62:727-35. (Pubitemid 44289503)
17. Wilkins JJ, Savic RM, KarlssonMO, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008; 52:2138-48. (Pubitemid 351758551)
18. Wilkins JJ, Langdon G,McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 2011; 72:51-62.
19. Selkon JB, Devadatta S, Kulkarni KG, et al. The emergence of isoniazidresistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull World Health Organ 1964; 31:294.
20. Yeager RL,MunroeWG, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952; 65: 523-46.
21. Vall-Spinosa A, Lester W, Moulding T, Davidson PT, McClatchy JK. Rifampin in the treatment of drug-resistant Mycobacterium tuberculosis infections. N Engl J Med 1970; 283:616-21.
22. Pasipanodya JG, Gumbo T. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother 2010; 54:2847-54.
23. Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007; 63:633-9. (Pubitemid 46911342)
24. Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007; 51:2994-6. (Pubitemid 47206244)
25. Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45:859-70. (Pubitemid 30348958)
26. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121:939-49. (Pubitemid 10118376)
27. McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 1954; 70:748-54.
28. YajkoDM,Wagner C, Tevere VJ, Kocagoz T, HadleyWK, ChambersHF. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay. J Clin Microbiol 1995; 33:1944-7.
29. Gangadharam PR, Devadatta S, Fox W, Nair CN, Selkon JB. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS. Bull World Health Organ 1961; 25:793-806.
30. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20:810-4.
31. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A replication clock for Mycobacterium tuberculosis. Nat Med 2009; 15:211-4.
32. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 2009; 15(Suppl 1):66-8.
33. Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1:2.
34. Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010; 14:560-70.
35. Visser ME, Grewal HM, Swart EC, et al. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr 2011; 93:93-100.
36. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843-7. (Pubitemid 29251017)
37. Zhang Y, Permar S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51:42-9. (Pubitemid 34060132)
38. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7:6-21. (Pubitemid 36427026)
39. Heifets LB, Lindholm-Levy PJ. Is pyrazinamide bactericidal against Mycobacterium tuberculosis? Am Rev Respir Dis 1990; 141:250-2. (Pubitemid 20023411)
40. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics- pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55:24-34.